Press Releases
  Date Title View
Sep 4, 2013
SAN DIEGO, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the Stifel Healthcare Conference 2013 on Wednesday, September 11, 2013 at ...
Jul 25, 2013
SAN DIEGO, July 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $11.00 per share...
Jun 14, 2013
Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. All shares of the common st...
FirstPrevious
...
12
= add release to Briefcase